Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Eya2, a Target Activated by Plzf, Is Critical for PLZF-RARA-Induced Leukemogenesis.

Ono R, Masuya M, Ishii S, Katayama N, Nosaka T.

Mol Cell Biol. 2017 Jun 15;37(13). pii: e00585-16. doi: 10.1128/MCB.00585-16. Print 2017 Jul 1.

2.

BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerization.

Gray F, Cho HJ, Shukla S, He S, Harris A, Boytsov B, Jaremko Ł, Jaremko M, Demeler B, Lawlor ER, Grembecka J, Cierpicki T.

Nat Commun. 2016 Nov 9;7:13343. doi: 10.1038/ncomms13343.

3.

Maintenance of leukemic cell identity by the activity of the Polycomb complex PRC1 in mice.

Rossi A, Ferrari KJ, Piunti A, Jammula S, Chiacchiera F, Mazzarella L, Scelfo A, Pelicci PG, Pasini D.

Sci Adv. 2016 Oct 7;2(10):e1600972. eCollection 2016 Oct.

4.

DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation.

Koya J, Kataoka K, Sato T, Bando M, Kato Y, Tsuruta-Kishino T, Kobayashi H, Narukawa K, Miyoshi H, Shirahige K, Kurokawa M.

Nat Commun. 2016 Mar 24;7:10924. doi: 10.1038/ncomms10924.

5.

PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia.

Cole CB, Verdoni AM, Ketkar S, Leight ER, Russler-Germain DA, Lamprecht TL, Demeter RT, Magrini V, Ley TJ.

J Clin Invest. 2016 Jan;126(1):85-98. doi: 10.1172/JCI82897. Epub 2015 Nov 23.

6.

Modeling epigenetic regulation of PRC1 protein accumulation in the cell cycle.

Dolbniak M, Kimmel M, Smieja J.

Biol Direct. 2015 Oct 12;10:62. doi: 10.1186/s13062-015-0078-1.

7.

Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Wang W, Qin JJ, Voruganti S, Nag S, Zhou J, Zhang R.

Med Res Rev. 2015 Nov;35(6):1220-67. doi: 10.1002/med.21358. Epub 2015 Jul 30. Review.

8.

PLZF regulates CCR6 and is critical for the acquisition and maintenance of the Th17 phenotype in human cells.

Singh SP, Zhang HH, Tsang H, Gardina PJ, Myers TG, Nagarajan V, Lee CH, Farber JM.

J Immunol. 2015 May 1;194(9):4350-61. doi: 10.4049/jimmunol.1401093. Epub 2015 Apr 1.

9.

Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies.

Arteaga MF, Mikesch JH, Fung TK, So CW.

Br J Cancer. 2015 Feb 3;112(3):413-8. doi: 10.1038/bjc.2014.374. Epub 2014 Sep 23. Review.

10.

Cbx2 stably associates with mitotic chromosomes via a PRC2- or PRC1-independent mechanism and is needed for recruiting PRC1 complex to mitotic chromosomes.

Zhen CY, Duc HN, Kokotovic M, Phiel CJ, Ren X.

Mol Biol Cell. 2014 Nov 15;25(23):3726-39. doi: 10.1091/mbc.E14-06-1109. Epub 2014 Sep 17.

11.

The epigenetic landscape of acute myeloid leukemia.

Conway O'Brien E, Prideaux S, Chevassut T.

Adv Hematol. 2014;2014:103175. doi: 10.1155/2014/103175. Epub 2014 Mar 23. Review.

12.

KAP1 represses differentiation-inducible genes in embryonic stem cells through cooperative binding with PRC1 and derepresses pluripotency-associated genes.

Cheng B, Ren X, Kerppola TK.

Mol Cell Biol. 2014 Jun;34(11):2075-91. doi: 10.1128/MCB.01729-13. Epub 2014 Mar 31.

13.

Chromatin modifiers and the promise of epigenetic therapy in acute leukemia.

Greenblatt SM, Nimer SD.

Leukemia. 2014 Jul;28(7):1396-406. doi: 10.1038/leu.2014.94. Epub 2014 Mar 10. Review.

14.

BMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progression.

Shen H, Chen Z, Ding X, Qi X, Cen J, Wang Y, Yao L, Chen Y.

J Cell Mol Med. 2014 Jun;18(6):1004-17. doi: 10.1111/jcmm.12246. Epub 2014 Feb 27.

15.

RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells.

Girard N, Tremblay M, Humbert M, Grondin B, Haman A, Labrecque J, Chen B, Chen Z, Chen SJ, Hoang T.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13522-7. doi: 10.1073/pnas.1310067110. Epub 2013 Jul 29.

16.

Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia.

Ridinger-Saison M, Evanno E, Gallais I, Rimmelé P, Selimoglu-Buet D, Sapharikas E, Moreau-Gachelin F, Guillouf C.

Cell Death Differ. 2013 Sep;20(9):1268-78. doi: 10.1038/cdd.2013.88. Epub 2013 Jul 12.

17.

Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.

Romanski A, Schwarz K, Keller M, Wietbrauk S, Vogel A, Roos J, Oancea C, Brill B, Krämer OH, Serve H, Ruthardt M, Bug G.

Cell Cycle. 2012 Sep 1;11(17):3219-26. doi: 10.4161/cc.21565. Epub 2012 Aug 16.

18.

Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins.

Boulay G, Dubuissez M, Van Rechem C, Forget A, Helin K, Ayrault O, Leprince D.

J Biol Chem. 2012 Mar 23;287(13):10509-24. doi: 10.1074/jbc.M111.320234. Epub 2012 Feb 7.

19.

The role of EZH2 in tumour progression.

Chang CJ, Hung MC.

Br J Cancer. 2012 Jan 17;106(2):243-7. doi: 10.1038/bjc.2011.551. Epub 2011 Dec 20. Review.

20.

Characterisation of genome-wide PLZF/RARA target genes.

Spicuglia S, Vincent-Fabert C, Benoukraf T, Tibéri G, Saurin AJ, Zacarias-Cabeza J, Grimwade D, Mills K, Calmels B, Bertucci F, Sieweke M, Ferrier P, Duprez E.

PLoS One. 2011;6(9):e24176. doi: 10.1371/journal.pone.0024176. Epub 2011 Sep 20.

Supplemental Content

Support Center